Updated Clinical Data from Combination of Margetuximab and Pembrolizumab in Gastric Cancer Presented at 2019 ASCO Gastrointestinal Cancers Symposium
MacroGenics, Inc. (MGNX)
Last macrogenics, inc. earnings: 11/6 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.macrogenics.com
Company Research
Source: GlobeNewswire
32.7% Objective response rate in HER2+ IHC 3+ second-line gastric cancer patientsWell tolerated in dose escalation and expansion cohorts ROCKVILLE, MD, Jan. 17, 2019 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced presentation of updated data from its Phase 2 clinical trial of margetuximab plus pembrolizumab for patients with advanced HER2+ gastric carcinoma in a poster session at the 2019 ASCO Gastrointestinal Cancers Symposium in San Francisco, California. The poster was titled "Antitumor Activity of Margetuximab plus Pembrolizumab in Patients with Advanced HER2+ (IHC3+) Gastric Carcinoma." This Phase 2 open-label, dose escalation study evaluates the combination of margetuximab, an investigational Fc-optimized anti-HER2 monoclonal antibody, with pembrolizumab, an anti-PD-1 an
Show less
Read more
Impact Snapshot
Event Time:
MGNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGNX alerts
High impacting MacroGenics, Inc. news events
Weekly update
A roundup of the hottest topics
MGNX
News
- MacroGenics, Inc. (NASDAQ: MGNX) was upgraded by analysts at TD Cowen from a "hold" rating to a "buy" rating.MarketBeat
- MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024 [Seeking Alpha]Seeking Alpha
- ARCA biopharma, Achilles Therapeutics, MSP Recovery among healthcare movers [Seeking Alpha]Seeking Alpha
- MacroGenics, Inc. (NASDAQ: MGNX) had its "market outperform" rating re-affirmed by analysts at JMP Securities.MarketBeat
- MacroGenics gains after mid-stage data for antibody drug conjugate [Seeking Alpha]Seeking Alpha
MGNX
Earnings
- 11/6/23 - Beat
MGNX
Sec Filings
- 4/8/24 - Form 4
- 4/8/24 - Form ARS
- 4/8/24 - Form DEFA14A
- MGNX's page on the SEC website